• Exendin-4 Research: Mechanism, Findings and Limits

  2026-10-07

  Exendin-4, also known as Exenatide, is a GLP-1 receptor agonist used in beta cell function research and type 2 diabetes research. This overview examines its biological context, the findings of a 2024 yeast-expression study, the difference between immunoreactive protein detection and demonstrated biological activity, and the limitations that constrain claims about affordability, oral delivery, and therapeutic translation.

• IL-7 and Viral ER Proteostasis: A Translational Lens

  2026-10-06

  A mechanistic perspective on how SARS-CoV-2 papain-like protease reshapes ER-associated protein regulation—and why IL-7 should be evaluated as an immune-context variable rather than presumed antiviral therapy. The analysis separates reported findings from translational hypotheses and defines where recombinant human IL-7 may support future research.

• Phytol and RXR Signaling: An Evidence-First View

  2026-10-06

  Phytol connects retinoid X receptor signaling with metabolism, GABAergic transmission modulation, and important chemical-identity questions. This evidence-first analysis also explains what a shaped bottlebrush polymer study can—and cannot—teach us about interpreting molecular biology data.

• Phytol: Evidence, Receptor Biology, and Research Limits

  2026-10-05

  A source-grounded overview of Phytol, including reported RXR activity, metabolism, GABAergic claims, antischistosomal research context, trans-Phytol limitations, and the boundaries of the supplied evidence.

• SARS-CoV-2 NSP15 Inhibitor Screening: Study Insights

  2026-10-05

  Vijayan and Gourinath combined structure-based virtual screening with molecular dynamics simulations to prioritize natural products predicted to bind the SARS-CoV-2 NSP15 endoribonuclease. Thymopentin and oleuropein emerged as leading computational candidates, but the findings remain hypothesis-generating because biochemical, cellular, pharmacokinetic, and clinical validation was not reported.

• Atorvastatin Beyond Lipids: A Translational Evidence Map

  2026-10-04

  Atorvastatin is more than an HMG-CoA reductase inhibitor: this evidence-focused review connects cholesterol metabolism research with ferroptosis, liver cancer, and vascular biology while separating preclinical promise from established conclusions.

• Recombinant Annexin V Purification: Evidence from 1993

  2026-10-03

  Burger and colleagues reported a rapid purification strategy for recombinant annexin V that combined gentle bacterial cell opening, calcium-dependent liposome binding, and ion-exchange chromatography. The study’s main contribution was a practical route to highly pure protein for crystallography, electron microscopy, spectroscopy, and single-channel measurements, although its evidence is specific to annexin V and the analytical standards of the early 1990s.

• FLAG tag Peptide: From Purification to Translation

  2026-10-01

  A mechanistic and translational guide to using the FLAG tag Peptide (DYKDDDDK) as more than a purification reagent. The article connects controlled epitope competition with antibody-binding kinetics, assay reproducibility, and strategic protein workflow design.

• Phytol Workflows for RXR Signaling and Assay Design

  2026-10-01

  Build more interpretable Phytol experiments by separating RXR-driven transcription from solvent, isomer, metabolic, and GABAergic effects. This guide combines cell-based dose design with a carefully bounded materials-science lesson from coil-bottlebrush polymer self-assembly.

• Ferroptosis Signature Identifies Atorvastatin in HCC

  2026-10-01

  This 2025 study combines a four-gene ferroptosis-related prognostic signature with Connectivity Map screening to identify atorvastatin as a candidate therapy for hepatocellular carcinoma. In vitro and in vivo experiments support atorvastatin-associated suppression of HCC growth and migration alongside ferroptosis induction, while also highlighting the need for independent and clinical validation.

• Ferroptosis Signature Identifies Atorvastatin in HCC

  2026-09-30

  A 2025 study combined ferroptosis-related transcriptomics, survival modeling, and Connectivity Map screening to develop a four-gene hepatocellular carcinoma prognostic signature and nominate Atorvastatin as a candidate therapeutic agent. Cell and animal experiments supported effects on HCC growth and migration that were consistent with ferroptosis, while also leaving important questions about mechanism, dose, and clinical transferability.

• Localized BDNF Release at Developing Neuromuscular Synapses

  2026-09-29

  This study identifies podosome-like structures as spatial hubs that capture and release muscle-derived BDNF during the earliest stages of neuromuscular junction assembly. Combining live imaging, loss-of-function experiments, proteolytic processing perturbation, and muscle-specific knockout mice, it links localized BDNF maturation to aneural and nerve-induced acetylcholine receptor clustering.

• SLC2A5 Fructose Metabolism in Primary CNS Lymphoma

  2026-09-29

  A 2026 Advanced Science study uses single-cell RNA and B-cell receptor profiling to connect the nutrient-poor, hypoxic primary CNS lymphoma microenvironment with SLC2A5-mediated fructose metabolism. Genetic and pharmacologic perturbations support SLC2A5 as a metabolic vulnerability in lymphoma cells and tumor-supportive macrophages, while also clarifying how tumor metabolism may contribute to T-cell dysfunction.

• MAPK10–KRT16 Control of NSCLC Metastasis

  2026-09-28

  The reference study identifies MAPK10 as a metastasis-suppressive kinase that phosphorylates KRT16 at Ser356 and Ser397, enabling RNF213-dependent ubiquitination and proteasomal degradation. Its integrated cellular, animal, and clinical analyses position the MAPK10/KRT16/RNF213 axis as a candidate prognostic framework while emphasizing the need for further validation before therapeutic translation.

• Phalloidin B7678: Practical F-Actin Workflow

  2026-09-28

  Phalloidin B7678 binds and stabilizes filamentous actin, supporting endpoint analysis of actin architecture in fixed or permeabilized samples and cell-free assays. It is not a fluorescent label by itself and is not appropriate for live-cell imaging or experiments that require reversible, unperturbed actin dynamics.

8060 records 1/538 page Next 12345 下5页 Last page